Literature DB >> 2445259

Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum.

S J Kish1, K Shannak, O Hornykiewicz.   

Abstract

We measured the rostrocaudal distribution of serotonin, dopamine, and their metabolites in Huntington's disease striatum (caudate and putamen). Mean levels of serotonin or 5-hydroxyindoleacetic acid were elevated in most striatal subdivisions, whereas concentrations of dopamine or its metabolite homovanillic acid were slightly to markedly reduced. Dopamine and serotonin were at control levels in the nucleus accumbens and substantia nigra. Whereas the above-normal serotonin can most likely be accounted for by striatal atrophy, the reduced dopamine suggests either a marked down-regulation of nigrostriatal dopamine neurons or an actual reduction in the arborization of the striatal dopamine neurons. As experimental animal data suggest, the relative excess of striatal serotonin or one of its metabolites may facilitate the neurodegenerative process in Huntington's disease striatum.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445259     DOI: 10.1002/ana.410220318

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

Review 1.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

2.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

3.  Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.

Authors:  Dan P Covey; Hannah M Dantrassy; Samantha E Yohn; Alberto Castro; P Jeffrey Conn; Yolanda Mateo; Joseph F Cheer
Journal:  Neuropsychopharmacology       Date:  2018-06-01       Impact factor: 7.853

Review 4.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

5.  Neocortical neurotransmitter markers in Huntington's disease.

Authors:  S J Pearson; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 6.  Genetics and neuropathology of Huntington's disease.

Authors:  Anton Reiner; Ioannis Dragatsis; Paula Dietrich
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

Review 7.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

8.  The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.

Authors:  Qi Peng; Naoki Masuda; Mali Jiang; Qing Li; Ming Zhao; Christopher A Ross; Wenzhen Duan
Journal:  Exp Neurol       Date:  2007-11-09       Impact factor: 5.330

9.  Plasma homovanillic acid and prolactin in Huntington's disease.

Authors:  Manolis Markianos; Marios Panas; Nikos Kalfakis; Dimitrios Vassilopoulos
Journal:  Neurochem Res       Date:  2008-10-08       Impact factor: 3.996

10.  Four decades of neurodegenerative disease research: how far we have come!

Authors:  Anne B Young
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.